thumb
July 29, 2021

Late-Breaking AAIC Presentation Explores Potential Clinical Effects of LECANEMAB (BAN2401)

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following  18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof of Concept Study at  2021 Alzheimer’s Association International Conference (AAIC)   Eisai Co., Ltd.

thumb
June 10, 2021

New Data at Cure SMA 2021 Highlight the Long-Term Efficacy of SPINRAZA® (nusinersen) and Biogen’s Commitment to Innovation in SMA Therapy

New data analysis suggests an investigational higher dose of SPINRAZA may lead to clinically meaningful improvements in motor function A NURTURE study analysis shows 92 percent of children who initiated SPINRAZA treatment as pre-symptomatic infants maintained the ability to swallow after

thumb
June 7, 2021

Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™

Programs now available to support patients and families with their treatment journey Collaborations with Veterans Health Administration, CVS Health and NAFC focused on health disparities in underserved communities Value-based agreements in progress with Cigna and other payers CAMBRIDGE, Mass.

thumb
June 7, 2021

FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease

The accumulation of amyloid beta plaques in the brain is a defining pathology of Alzheimer’s disease In clinical trials, ADUHELM reduced amyloid beta plaques by 59 to 71 percent at 18 months of treatment CAMBRIDGE, Mass. and TOKYO, June 07, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai ,

thumb
June 1, 2021

Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra® (Tocilizumab)

The comparative study met its primary endpoints and showed equivalent efficacy and comparable safety profile in patients with moderate-to-severe rheumatoid arthritis CAMBRIDGE, Mass. and GUANGZHOU, China, June 01, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd.

thumb
May 25, 2021

Biogen Announces Webcast of Annual Meeting of Stockholders

Cambridge, Mass. – Biogen Inc. (Nasdaq: BIIB) announced today that the webcast of the Company's 2021 Annual Meeting of Stockholders will be held on Wednesday, June 2, 2021 at 9:00 a.m. Eastern Time. A live audio webcast of the meeting will be available on the Investor Relations section of the

thumb
May 21, 2021

Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform

Collaboration aims to develop a next-generation AAV production platform to help accelerate Biogen’s efforts to bring novel gene therapies to patients worldwide Ginkgo’s synthetic biology expertise may enable the expansion of therapeutic utility and overcome development challenges of viral vectors

thumb
May 20, 2021

Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, Switzerland

CAMBRIDGE, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Biogen Inc.  (Nasdaq: BIIB) today announced that its next generation manufacturing facility in Solothurn, Switzerland has received a Good Manufacturing Practice (GMP) multi-product license from the Swiss Agency for Therapeutic Products

thumb
May 14, 2021

Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP

While the Phase 2/3 XIRIUS study did not meet its primary endpoint, data indicated positive trends in several prespecified secondary endpoints, such as a clinically relevant measure of visual acuity Biogen will communicate next steps for the program after analyzing the complete data set Currently

thumb
May 13, 2021

Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research

As part of the agreement, Biogen will leverage Envisagenics’ AI platform with the goal of better understanding Central Nervous System diseases CAMBRIDGE, Mass. and NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Envisagenics today announced a new collaboration to advance

thumb
May 12, 2021

Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data

TMS-007 has the potential to be a next generation thrombolytic with an improved benefit-risk profile Acute ischemic stroke is caused by a blockage of blood supply to the brain, and current thrombolytics are limited in use due in part to increased risks of bleeding Phase 2a study demonstrated